GenSight Biologics is a Bronze sponsor at the OIS event.
Dr Magali Taiel, Chief Medical Officer, will present GenSight and its latest news about our most advanced product called LUMEVOQ® (GS010; lenadogene nolparvovec), a gene therapy targeting Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease leading to blindness in young adults. The LUMEVOQ®
- Day: Thursday October 7, 2021
- Time: 09 am CDT